<DOC>
	<DOCNO>NCT01974830</DOCNO>
	<brief_summary>This longitudinal , observational , non-interventional registry study , design collect retrospective prospective real world data , patient receive Alpha-1 augmentation therapy home Coram Specialty Infusion.The data collect standard Coram homecare form , well patient report case form .</brief_summary>
	<brief_title>AL1TER™ : Alpha-1 Therapy , Evaluation , Research Patient Registry</brief_title>
	<detailed_description>This longitudinal , observational , non-interventional registry study , design collect retrospective prospective data , order acquire real-world data product prescribing , product use patient , product performance patient receive α1-PI therapy homecare and/or Coram ambulatory infusion suite . There limit number subject may participate registry . The AL1TER Registry overseen Principal Investigator list first page protocol . No le 40 physician US participate registry ; upper limit number . All patient ≥18 year old , member vulnerable study population , require α1-PI therapy may invite participate study . Participation AL1TER Registry continue long subject : Being treat α1-PI therapy use Coram 's infusion service , Using insurance carrier Coram approve provider , Willing participate registry , Until Sponsor , Principal Investigator subject decides terminate participation . The data collection study differs registry data go AL1TER Registry collect homecare agency personnel ( i.e. , pharmacists nurse ) . The data collect standard Coram homecare form . AL1TER Registry data enter Coram 's standard patient database process manner non-registry patient extract systematic fashion incorporation AL1TER Registry . Data collect St. George Respiratory Questionnaire ( SGRQ ) , Life Quality index Questionnaire ( LQIQ ) , subject medical chart review may also enter AL1TER Registry database . All data de-identified use reporting result database . All subject participate AL1TER Registry inform Registry submit investigator , designee . Additionally physician permission , registry staff contact patient via mail phone consent , patient accept Coram 's service agree start therapy . Collection subject data incorporation AL1TER Registry begin subject sign inform consent form . In addition standard visit/data collection already carry Coram , subject also ask complete two short quality life questionnaire every six month begin 30 day date subject sign inform consent . This registry study continue time sponsor , Coram Clinical Trials , make decision terminate data collection . At time submit investigator , subject IRB notify study termination . Subject participation begin date sign inform consent continue sponsor , Principal Investigator , submit investigator , subject decides terminate participation registry terminate . The authorization subject use Protected Health Information ( PHI ) AL1TER Registry expiration date . The AL1TER Registry involve compilation standard data collect patient receive α1-PI therapy within Coram system ; data collect SGRQ LQIQI , relevant item patient medical history , include pulmonary function test . Since registry retrospective prospective , forms start patient care , end care make available entry registry , even form predate sign ICF . Sample form standard data collect Coram patient include appendix . The information capture α1-PI patient use Coram 's standard form may include : Patient Start Care : Patient information ( contact , date birth , height , weight , gender , tobacco/alcohol/drug use ) Age time development symptom , age time diagnosis Medical/surgical history Alpha-1 Genotype Baseline FEV1 value Therapy safety review ( diagnosis , therapy , administration method , PICC length , date insertion , etc . ) Care plan Ongoing Patient Assessment : Patient information Changes dose Infections/illness Antibiotic use Primary care physician visit Emergency room visit Hospitalizations Effects infusions Other change health Care plan update ( ) Clinical monitoring ( lab value , weight , nutrition screen , FEV1 value . ) Home Visit Assessments : Patient information Therapy information Medical history medication ( initial ongoing ) Vital signs/weight Patient/home safety Access device infusion therapy Nursing intervention Assessments : respiratory , cardiovascular , gastrointestinal , genitourinary , musculoskeletal , neurosensory , integumentary , endocrine , pain Medication administration information Teaching compliance Insurance Information Insurance carrier Insurance coverage Reimbursement variance</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<criteria>Patients must meet follow criterion participate study : Signed informed consent Either male female , ≥18yrs age require α1PI therapy Agree use Coram 's infusion service upon entry AL1TER Registry Patients exclude participation study follow reason : Currently use insurance provider Coram 's service covered/authorized Have previously participate AL1TER Registry revoke consent use Protected Health Information theAL1TER Registry database Under age 18 , member vulnerable population ( prisoner , unable understand English version consent , unable sign consent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>alpha-1</keyword>
	<keyword>anti-trypsin</keyword>
	<keyword>pulmonary function</keyword>
	<keyword>augmentation therayp</keyword>
	<keyword>home care</keyword>
</DOC>